Still have questions about our products?
Our scientists can help you choose the right assay format, substrate, and enzyme for your experiment.
Also known as: ABL • JTK7 • c-ABL • v-abl • p150 • BCR-ABL • Abelson murine leukemia viral oncogene 1 • V-abl Abelson murine leukemia viral oncogene 1
ABL1 at a glance. ABL1 activity is measured continuously and directly with the PhosphoSens® AQT0032 substrate, or as an endpoint TRF readout with AQT0030, with no antibodies or coupling enzymes.
ABL1 (ABL proto-oncogene 1) is a non-receptor tyrosine kinase belonging to the Abl family, which includes ABL1 and ABL2 (ARG). Under normal physiological conditions, ABL1 activity is tightly regulated through intramolecular autoinhibition, with the SH3 and SH2 domains clamping the kinase domain in an inactive conformation. Activation occurs via displacement of this autoinhibitory clamp by upstream signals, scaffolding proteins, or oncogenic rearrangements. Key substrates include CRKL, STAT5, FAK, and the adaptor protein DOK1, linking ABL1 to cell proliferation, survival, cytoskeletal remodeling, and DNA damage response. In chronic myelogenous leukemia (CML) and a subset of acute lymphoblastic leukemias (ALL), the chromosomal translocation t(9;22) generates the BCR-ABL1 fusion oncoprotein, constitutively activating kinase activity and driving uncontrolled myeloid expansion. This makes ABL1 one of the most validated oncology drug targets in history, and the success of imatinib as a molecularly targeted therapy established the proof-of-concept for kinase inhibitor drug discovery across oncology.
Profiling ABL1 inhibitors presents several assay challenges: the kinase is frequently studied at physiological ATP concentrations to accurately capture competitive inhibitor potency, and the BCR-ABL1 fusion introduces complex regulatory dynamics that can confound endpoint measurements. Traditional ADP-Glo and HTRF assays require incubation stop points that miss transient kinetic phenomena such as slow-on/slow-off binding, covalent inactivation (kinact/KI), and induced-fit mechanisms critical for third-generation inhibitors like ponatinib and asciminib. Radiometric formats add safety and throughput limitations. AssayQuant's PhosphoSens continuous fluorescent assay monitors substrate phosphorylation in real time using physiological ATP, generating full progress curves that capture time-dependent inhibition, covalent kinact/KI parameters, and inhibitor mechanism of action without the endpoint artifacts that can misclassify allosteric STAMP inhibitors like asciminib.
Have questions about ABL1 assay design, selectivity panels, or covalent inhibitor characterization?
Ask Our Scientists →Continuous, real-time fluorescent assays optimized for quantitative ABL1 activity measurements, IC50 determination, and mechanistic studies.
PhosphoSens-Kinetic assays directly quantify enzyme activity by continuously monitoring substrate phosphorylation or dephosphorylation in real time, generating a full progress curve in every well.
Learn more about PhosphoSens-Kinetic →Need pricing or availability? Select a kit or substrate to request a quote below.
Kits
Substrate: AQT0032
Ready-to-use assay kits containing substrate and all essential reagents.
Automatically save 10% when bundling 10ug recombinant enzyme with your 1,000 assay kit. View enzymes
Substrate
See every target AQT0032 assays →
Bulk PhosphoSens® substrate for assay development and high-throughput workflows.
Automatically save 10% when bundling Reagent Packs with your substrate. View Reagent Packs
One substrate, many targets
AQT0032 also assays ABL2, plus 9 other ABL1 variants
Validated with the same PhosphoSens® substrate, so you can run a selectivity panel in one assay format.
Select a kit, substrate, or enzyme above. Our team will confirm pricing, availability, and any applicable bundle discounts.
No PhosphoSens-Red format is currently available for ABL1.
Select a kit, substrate, or enzyme above. Our team will confirm pricing, availability, and any applicable bundle discounts.
Wild-type and mutant forms of ABL1 for assay development, kinase profiling, and mechanistic studies. Enzymes are supplied active and optimized for PhosphoSens® substrates.
| Enzyme | Catalog # | Tag / expression | Size & price | Add to quote |
|---|---|---|---|---|
ABL1, Active
Specifications
|
AQT-A03-11H | N-His Baculovirus / Sf9 |
||
ABL1 (E255K), Active
Specifications
|
AQT-A03-12BG | N-GST Baculovirus / Sf9 |
||
ABL1 (T315I), Active
Specifications
|
AQT-A03-12DG | N-GST Baculovirus / Sf9 |
||
ABL1 (Y253F), Active
Specifications
|
AQT-A03-12EG | N-GST Baculovirus / Sf9 |
||
ABL1 (Q252H), Active
Specifications
|
AQT-A03-12FG | N-GST Baculovirus / Sf9 |
||
ABL1 (Y253H), Active
Specifications
|
AQT-A03-12GH | N-His Baculovirus / Sf9 |
||
ABL1 (E255V), Active
Specifications
|
AQT-A03-12HH | N-His Baculovirus / Sf9 |
||
ABL1 (F317L), Active
Specifications
|
AQT-A03-12IG | N-GST Baculovirus / Sf9 |
||
ABL1 (F317I), Active
Specifications
|
AQT-A03-12JG | N-GST Baculovirus / Sf9 |
||
ABL1 (M351T), Active
Specifications
|
AQT-A03-12KG | N-GST Baculovirus / Sf9 |
||
ABL1 (H396P), Active
Specifications
|
AQT-A03-12LG | N-GST Baculovirus / Sf9 |
||
ABL1 (V299L), Active
Specifications
|
AQT-A03-12MG | N-GST Baculovirus / Sf9 |
||
ABL1 (Y245F), Active
Specifications
|
AQT-A03-12PH | N-His Baculovirus / Sf9 |
||
ABL1 (Y245F Y412F), Active
Specifications
|
AQT-A03-12QH | N-His Baculovirus / Sf9 |
No variants match that filter.
Most cellular ATP concentrations range from 1 to 5 mM, and competitive inhibitor IC50 values are highly sensitive to ATP concentration due to the Cheng-Prusoff relationship. Assays run at artificially low ATP levels can dramatically underestimate inhibitor potency relative to the cellular environment. AssayQuant PhosphoSens assays are validated at physiological ATP concentrations, providing IC50 and Ki values with direct translational relevance.
Yes. Because PhosphoSens generates continuous real-time progress curves, the kinetic signatures of allosteric inhibitors targeting the ABL1 myristoyl-binding pocket differ measurably from ATP-competitive mechanisms, enabling mechanistic classification. This is particularly valuable for characterizing STAMP inhibitors and combination inhibitor strategies where distinguishing mechanism of action is critical for lead optimization.
PhosphoSens continuously monitors phosphorylation over time, allowing direct observation of the time-dependent loss of enzyme activity characteristic of covalent or slow-binding inhibitors. From these progress curves, kinact and KI parameters can be extracted, which are not accessible from single-timepoint endpoint assays such as ADP-Glo or HTRF, making PhosphoSens essential for covalent ABL1 inhibitor programs.
Peer-reviewed studies that used AssayQuant assays, substrates or services for ABL1.
Explore data and documents to support your kinase and phosphatase experiments. Download sample data, protocols and other resources to see how our assays perform and to help you get started in your own lab. All validation data generated using PhosphoSens® assays under recommended conditions.
Each validation report provides experimental conditions and data showing:
Protocol
See how the PhosphoSens-Kinetic Assay can be used to find the IC50 of a kinase inhibitor.
Download Protocol →Webinar
Discover how continuous assay formats power deep understanding of kinase function. See how PhosphoSens® assays guide inhibitor profiling, selectivity assessment, and mechanistic characterization.
Watch the Webinar →Service
Need broader selectivity data? KinSight profiling runs your compounds across our full kinase panel under identical PhosphoSens conditions.
Learn about KinSight →Want to hear the latest about our technology? Be among the first to learn about our latest products and services.